Protalix BioTherapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-6.6M | $2.9M | $8.3M | $-14.9M | $-27.6M | $-6.5M | $-18.3M | $-26.5M |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $1.5M | $1.3M | $1.2M | $1.1M | $1.1M | $1.3M | $1.6M | $1.7M |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $2.3M | $3.3M | $3.4M | $2.1M | $2.4M | $3.1M | $835.0K | $514.0K |
| Net Cash from Operating Activities | $-12.0M | $8.7M | $-1.3M | $-25.0M | $-10.3M | $-26.1M | $-19.4M | $-7.7M |
| Investing Activities | ||||||||
| Capital Expenditures | $1.6M | $1.3M | $1.1M | $628.0K | $1.5M | $655.0K | $627.0K | $686.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.4M | $4.2M | $-16.7M | $-5.0M | $18.9M | $-20.0M | $-883.0K | $-591.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.3M | $-16.8M | $24.7M | $8.2M | $12.1M | $46.5M | $0 | $-4.8M |
| Net Change in Cash | $-5.1M | $-3.9M | $6.5M | $-21.9M | $20.7M | $473.0K | $-20.0M | $-13.4M |
| Free Cash Flow | $-13.6M | $7.4M | $-2.5M | $-25.6M | $-11.7M | $-26.8M | $-20.0M | $-8.4M |